GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shanghai Haohai Biological Technology Co Ltd (STU:5HB) » Definitions » Cash Flow from Operations

Shanghai Haohai Biological Technology Co (STU:5HB) Cash Flow from Operations : €55.0 Mil (TTM As of Jun. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Shanghai Haohai Biological Technology Co Cash Flow from Operations?

Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.

For the three months ended in Jun. 2024, Shanghai Haohai Biological Technology Co's Net Income From Continuing Operations was €16.0 Mil. Its Depreciation, Depletion and Amortization was €0.0 Mil. Its Change In Working Capital was €0.0 Mil. Its cash flow from deferred tax was €0.0 Mil. Its Cash from Discontinued Operating Activities was €0.0 Mil. Its Asset Impairment Charge was €0.0 Mil. Its Stock Based Compensation was €0.0 Mil. And its Cash Flow from Others was €16.3 Mil. In all, Shanghai Haohai Biological Technology Co's Cash Flow from Operations for the three months ended in Jun. 2024 was €32.3 Mil.


Shanghai Haohai Biological Technology Co Cash Flow from Operations Historical Data

The historical data trend for Shanghai Haohai Biological Technology Co's Cash Flow from Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shanghai Haohai Biological Technology Co Cash Flow from Operations Chart

Shanghai Haohai Biological Technology Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow from Operations
Get a 7-Day Free Trial Premium Member Only Premium Member Only 44.77 32.94 47.56 31.32 81.48

Shanghai Haohai Biological Technology Co Quarterly Data
Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Cash Flow from Operations Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.81 - 9.71 32.34 13.01

Shanghai Haohai Biological Technology Co Cash Flow from Operations Calculation

Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.

Shanghai Haohai Biological Technology Co's Cash Flow from Operations for the fiscal year that ended in Dec. 2023 is calculated as:

Shanghai Haohai Biological Technology Co's Cash Flow from Operations for the quarter that ended in Jun. 2024 is:


Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €55.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Shanghai Haohai Biological Technology Co  (STU:5HB) Cash Flow from Operations Explanation

For companies reported in indirect method, cash flow from operations contains six items:

1. Net Income From Continuing Operations:
Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Shanghai Haohai Biological Technology Co's net income from continuing operations for the three months ended in Jun. 2024 was €16.0 Mil.

2. Depreciation, Depletion and Amortization:
Depreciation is a present expense that accounts for the past cost of an asset that is now providing benefits.
Depletion and amortization are synonyms for depreciation.
Generally:
The term depreciation is used when discussing man made tangible assets
The term depletion is used when discussing natural tangible assets
The term amortization is used when discussing intangible assets

Shanghai Haohai Biological Technology Co's depreciation, depletion and amortization for the three months ended in Jun. 2024 was €0.0 Mil.

3. Change In Working Capital:
Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities. Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow.

Shanghai Haohai Biological Technology Co's change in working capital for the three months ended in Jun. 2024 was €0.0 Mil. It means Shanghai Haohai Biological Technology Co's working capital {id_Q12} from Mar. 2024 to Jun. 2024 .

4. Deferred Tax:
It is the cash flow generated from deferred tax.

Shanghai Haohai Biological Technology Co's cash flow from deferred tax for the three months ended in Jun. 2024 was €0.0 Mil.

5. Cash from Discontinued Operating Activities:
Net cash from all of the entity's discontinued operating activities.

Shanghai Haohai Biological Technology Co's cash from discontinued operating Activities for the three months ended in Jun. 2024 was €0.0 Mil.

6. Asset Impairment Charge:
It is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Shanghai Haohai Biological Technology Co's asset impairment charge for the three months ended in Jun. 2024 was €0.0 Mil.

7. Stock Based Compensation:
It is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Shanghai Haohai Biological Technology Co's stock based compensation for the three months ended in Jun. 2024 was €0.0 Mil.

8. Cash Flow from Others:
These are cash differences caused by the change of inventory, accounts payable, accounts receivable etc. For instance, if a company pays its suppliers slower, its cash position will build up faster. If a company receives payments from its customers slower, its account receivables will rise, and its cash position will grow more slowly (or even shrink).

Shanghai Haohai Biological Technology Co's cash flow from others for the three months ended in Jun. 2024 was €16.3 Mil.


Shanghai Haohai Biological Technology Co Cash Flow from Operations Related Terms

Thank you for viewing the detailed overview of Shanghai Haohai Biological Technology Co's Cash Flow from Operations provided by GuruFocus.com. Please click on the following links to see related term pages.


Shanghai Haohai Biological Technology Co Business Description

Traded in Other Exchanges
Address
No. 1386 Hongqiao Road, 23rd Floor, WenGuang Plaza, Changning District, Shanghai, CHN
Shanghai Haohai Biological Technology Co Ltd is engaged in the manufacturing and sale of biologicals, medical hyaluronate, and ophthalmology products. The Company's operating activities are related to single operating segment which is the manufacture and sale of biologicals, medical hyaluronate and intraocular lens, research and development of biological engineering and pharmaceutical products and the provision of related services. Its products are categorized into four types comprising ophthalmology, medical aesthetics, orthopedics, and anti-adhesion. Geographically, it has operations in Mainland China which is the key revenue driver, the United States, the United Kingdom, and other countries.

Shanghai Haohai Biological Technology Co Headlines

No Headlines